| Literature DB >> 32576138 |
Rafaella F A Costa1,2, Maria L A Ferrari3,4, Marie-Agnès Bringer5, Arlette Darfeuille-Michaud2, Flaviano S Martins1, Nicolas Barnich6.
Abstract
BACKGROUND: Crohn's disease (CD) is characterized by chronic inflammation of the human intestine. Several studies have demonstrated that the intestinal mucosa of CD patients in Western countries is abnormally colonized by adherent-invasive Escherichia coli (AIEC) strains. However, no studies to date have focused on the involvement of such E. coli strains in CD patients in Brazil. Here, we characterized E. coli strains associated with the ileal mucosa of Brazilian CD patients (ileal biopsies from 35 subjects, 24 CD patients and 11 controls).Entities:
Keywords: Crohn’s disease; Inflammatory bowel disease; Mucosa-associated Escherichia coli
Mesh:
Substances:
Year: 2020 PMID: 32576138 PMCID: PMC7310525 DOI: 10.1186/s12866-020-01856-x
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Patient characteristics
| Patients | N | Gender | Age (Years) | |
|---|---|---|---|---|
| Average ± SD | Age range | |||
| Control | 11 | 6/5 | 57.1 ± 13.4 | 28–81 |
| CD | 24 | 16/8 | 42.3 ± 12.0 | 18–66 |
| 35 | 22/13 | 46.1 ± 12.9 | 18–81 | |
N number, F female, M male, SD standard deviation
Montreal classification of Crohn’s disease
| Criteria | n (%) |
|---|---|
| A1: 16 years or less | 2 (8.3%) |
| A2: 17–40 years | 17 (70.8%) |
| A3: 40 years or more | 5 (20.8%) |
| L1: Terminal Ileum | 9 (37.5%) |
| L2: Colon | 1 (4.2%) |
| L3: Ileocolonic | 14 (58.3%) |
| B1: Not stenting, non-penetrating | 5 (20.8%) |
| B2: Stenting | 8 (33.3%) |
| B3: Penetrating | 6 (25.0%) |
| B1p: Not stenting, non-penetrating + perianal fistula | 1 (4.2%) |
| B2p: stenting + perianal fistula | 2 (8.3%) |
| B3p: penetrating + perianal fistula | 2 (8.3%) |
Fig. 1Quantification of Enterobacteriaceae associated with the ileal mucosa of controls and patients with CD. The value of the median is shown in red. The statistical analysis was performed using the nonparametric Mann-Whitney test. * p < 0.05
Distribution of E. coli strains among the phylogenetic groups
| Patients | Strains | Phylogenetic groups | |||
|---|---|---|---|---|---|
| A | B1 | B2 | D | ||
| Control | 58 | 26 (44.83%) | 8 (13.79%) | 3 (5.17%) | 21 (36.21%) |
| CD | 183 | 68 (37.16%) | 51 (27.87%) | 21 (11.48%) | 43 (23.50%) |
aThe statistical analysis was performed by the Kruskal-Wallis test adjusted by Dunn’s test. No statistical difference was observed
Fig. 2Invasive ability of E. coli strains. The results are expressed as the percentage of inoculum surviving in human Intestine-407 epithelial intestinal cells after 3 h of infection and 1 h of gentamicin treatment. The value of the median is shown in red. The statistical analysis was performed using the nonparametric Mann-Whitney test. n.s. p > 0.05
Fig. 3Survival and replication of E. coli strains within THP-1 cells. CTL, control subject samples; CD, CD patient samples. The statistical analysis was performed using a nonparametric Mann-Whitney test to determine if the value corresponding to the number of intracellular bacteria at 6 h post-infection was significantly higher than the value at 1 h post infection for each strain. * p < 0.05
Fig. 4TNF-α levels produced by THP-1 cells infected with AIEC strains. CTL, control subject samples; CD, CD patient samples. Statistical analysis was performed by one-way ANOVA followed by the Newman-Keuls test. ** p < 0.01, *** p < 0.001 (compared to noninfected cells)
Analysis of the presence of putative virulence factors in AIEC strains
| Strains | Phylogroup | ||||
|---|---|---|---|---|---|
| LF82 | B2 | + | + | + | + |
| CTL1 | B2 | – | + | – | – |
| CTL2 | D | + | – | – | – |
| CTL4 | A | – | – | – | – |
| CD1 | B1 | – | – | + | – |
| CD2 | B1 | – | – | + | – |
| CD3 | B2 | – | – | – | – |
| CD4 | B1 | – | – | – | – |
| CD5 | B1 | – | – | – | – |
| CD6 | B1 | – | – | – | – |
Substitutions of amino acid residues in the AIEC strains
| Strains | Mutations at amino acid residue | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Leader Lectin domain Pilin domain peptide | ||||||||||
| 6 | 26 | 27 | 66 | 70 | 78 | 119 | 158 | 202 | 269 | |
| LF82 | A | S | N | P | ||||||
| CTL1 | A | K | ||||||||
| CTL2 | ||||||||||
| CTL4 | A | S | V | |||||||
| DC1 | L | A | ||||||||
| DC2 | L | A | ||||||||
| DC3 | A | H | ||||||||
| DC4 | A | |||||||||
| DC5 | A | |||||||||
| DC6 | A | |||||||||
Primer sequences and PCR conditions used to detect the hcp1, hcp3, lpfA, gipA and fimH genes
| Gene | Primer sequencing (5’- 3′) | PCR conditions | Product (pb) | Reference |
|---|---|---|---|---|
F: AAACACCACTGGAGTACCTG R: TGGTACTTAGCAAGAAAGAGC | 95 °C 3 min., 35 cycles (95 °C 45 s., 55 °C 30 s, e 72 °C 45 s.) e 68 °C 8 min. | 999 | This study | |
F: CGAAATCAGTCTTGTTCCGC R: GGGTTTCCTTATCGTGTTCT | 95 °C 3 min., 35 cycles (95 °C 45 s., 55 °C 30 s, e 72 °C 45 s.) e 68 °C 8 min. | 745 | This study | |
F: GGCCTTCTTTCAGACGGTA R: CTGGAAAACTGCGATATCTCC | 95 °C 3 min., 35 cycles (95 °C 45 s., 57 °C 30 s, e 72 °C 45 s.) e 68 °C 8 min. | 199 | [ | |
F: GTCGTTGCGCCACCAACAA R: ACGGCGCAGATGGTAATTCT | 94 °C 5 min., 35 cycles (94 °C 1 m., 55 °C 1 m, e 72 °C 30 s.) e 72 °C 10 min. | 200 | [ | |
F: ATTCCTCACAATCAGCGCAC R: CGCGTCTTATCTGGCCTACA | 95 °C 3 min., 35 cycles (95 °C 45 s., 57 °C 30 s, e 72 °C 45 s.) e 68 °C 8 min. | 1125 | This study |